COL1A1 novel splice variant in osteogenesis imperfecta and splicing variants review: A case report

Michella Dirani, Victor D. Cuenca and Vanessa I. Romero*
School of Medicine, Universidad San Francisco de Quito, Quito, Ecuador

Background: Osteogenesis imperfecta (OI) is a rare heterogeneous genetic disorder commonly autosomal dominant with variants in the COL1A1 and COL1A2 genes. It is characterized by bone fragility and deformity, recurrent fractures, blue sclera, dentinogenesis imperfecta, short stature, and progressive deafness.

Case presentation: We present a novel splicing mutation in the COL1A1 gene (c.2398-1G > C) in a 6-year-old Ecuadorian girl with fractures after light pressure and blue sclera. We identified the pathogenic variant, performed a literature review of splice variants, and recognized their location in the COL1A1 functional domains.

Conclusion: We describe the first clinical description of a patient with OI type 1 caused by a splice variant in intron 34 of COL1A1 gene and identify that most of them are localized in the triple-helical region domain. We suggest that the splice variant in signal peptide, von Willebrand factor type C, and nonhelical regions maintain their functionality or that individuals affected with severe cases die early in development and are not reported.

KEYWORDS
osteogenesis imperfecta, splicing, Ecuador, COL1A1, collagen

Introduction

Osteogenesis imperfecta (OI) known as brittle bone disease is a rare heterogeneous genetic disorder of connective tissue with an incidence of 1 in 15,000–20,000 births (1). Clinically it is characterized by bone fragility, deformity, recurrent fractures, blue sclera, dentinogenesis imperfecta, short stature, and progressive deafness (1). Under clinical and radiological parameters, the disease is classified according to the Sillence classification in four types: I (mild) and IV (moderate deforming), frequent but less severe; II (lethal) and III (severe deforming), less frequent but more lethal (3).

OI is mostly autosomal dominant and 95% of cases result from mutations in COL1A1 and COL1A2 that code for type 1 collagen alpha chains, α1 and α2, respectively (1). Autosomal recessive cases result from mutations in the CRTAP and LEPRE1 genes (3). COL1A1 variants include missense, nonsense, frameshift, and splice site (4). RNA splicing is indispensable for protein synthesis. The RNA transcript (pre-mRNA) requires introns being spliced and the exons bound to form mRNA (1). The splicing process is performed by the spliceosome, which consists of five uridine-rich
ribonucleoproteins and more than 200 associated proteins (4).
Inappropriate splicing fails to remove introns or removes
necessary exons resulting in an abnormal type I collagen
chain (5).

Here, we report a patient with fractures after light pressure
and blue sclera, identify the pathogenic variant, performed a
literature review of splice variants, and recognized their
location in the COL1A1 functional domains. Most of articles
focus on nonsense and missense variants and splice variant
information are not available.

Case report

Patient information and therapeutic interventions

We report a 6-year-old female who came to the genetic
outpatient clinic for multiple consecutive fractures. She was
born by vaginal delivery from nonconsanguineous parents
with no complications and achieved all developmental
milestones without delay. These include fine motor, gross
motor social-emotional, and behavioral, language, and
cognitive milestones (6). At 6 months, she presented hip
dysplasia and bilateral valgus cavus that was treated with an
orthopedic diaper. In June 2021, she fell from her height and
suffered a left femoral shaft close fracture that required
surgery and plating nailing placement (Figure 1 and
Supplementary Figure S1). Eight months later, the surgeon
removed the plating. Fifteen days later, the girl slightly twisted
her left leg and fractured her left femur again. The
pediatrician ordered additional imaging studies and ruled out
malignancy. Her physical examination revealed blue sclera
without coloboma and hypermobility in her hands and feet.
Her family history information is relevant for blue sclera but
no fractures in her mother.

Molecular analysis

We ordered the Osteogenesis Imperfecta and Bone Fragility
Panel that analyzes 67 genes and identified a heterozygous G >
C c.2398-1 (splice acceptor) pathogenic variant in intron 34 of
COL1A1. The variant alters splicing with a frequency of 0 in
The Genome Aggregation Database (gnomAD) and in The
Exome Aggregation Consortium (ExAC) databases. The splice
variant was confirmed by Sanger sequencing.

Review of splicing variants

We reviewed all cases of splicing variants reported in
PubMed until June 2022 and filtered the case reports that
include the splice variant location and the OI type. We
identified 336 splicing variants, most of them were OI type I
and located in intron 17. Most of the splice variants were
located in introns 28, 33, 35, and 50 and in exon 49
(Figure 2, Supplementary Tables S1, S2). OI type I was
located mostly in intron 17 and 19; type 2 in intron 14, 26,
and 47; type 3 in intron 11 and 6; and type 4 in intron 8, 9,
15, 16, and 19. The most intron splice variants were located
in introns near exons that become the triple-helical region
domain (Supplementary Table S2). Splice variant mostly
caused OI type 1. Intron 17 includes the most single
nucleotide variants (mostly G > C/A) and reported 17 type 1,
3 type 3, and 1 type 4 case. Most of single nucleotide variants

FIGURE 1
Patient’s x-rays. First x-ray shows the initial left femoral shaft fracture. Second x-ray shows the first plating fixation. Third x-ray shows the fracture after
a slight twist of the leg. Fourth x-ray shows the second plating fixation.
Discussion

In this case report, we describe the first clinical description of a patient with a splice variant in intron 34 in the COL1A1 gene with a systemic literature review of splice variants reported in PubMed and used the variant database by Dalgeish et al. We identified that most of the variants localize in the triple-helical region domain.

Our patient presented with two fractures after weak pressure and blue sclera, and neoplasia was excluded. The sequencing panel reported a splice variant in intron 34. A splice variant in exon 34 was reported by Lindahl et al., and a study in Sweden mentioned that one case had OI type IA and did not include the clinical description (7). Our case is the first report of a c.2398-1G > C variant, is OI type I, and the mother of the patient has blue sclera and lacks medical history of fractures.

The differential diagnoses of OI include diseases related to bone fragility (8). Rickets was excluded due to a normal alkaline phosphatase level, normal sclera and audition involvement, or deafness. Osteomalacia is characterized by bone pain and fractures (8). Other disorders to consider include Bruck’s syndrome (congenital contractures involving knee or ankle joints), panostotic fibrous dysplasia (cystic lesions in all bones), juvenile Paget’s disease (elevated alkaline phosphatase levels), or juvenile idiopathic osteoporosis (9).

The COL1A1 gene is located in chromosome 17, includes 17,554 bp, and produces pro-alpha 1 collagen chains. Type 1 collagen is the most common type of collagen in the body and is part of bones, skin, tendons, and sclera (10). Type 1 collagen contains two pro-alpha 1 chains and one pro-alpha 2 chain. The functional domains include signal peptide (exon 1), von Willebrand factor type C and nonhelical region (N-terminal), white rectangle = triple-helical region, and dark gray rectangle = nonhelical region (C-terminal).

Examples of different phenotypes by different splice variants

Splice variants in the same gene can cause different phenotypes. Errors during splicing leads to alterations in the reading frame by including introns or excluding exons. For example, the variant c.3718-2477G>T in CFTR that is reported in patients with cystic fibrosis produces a stop
codon, creates a nonfunctional protein, and present a mild phenotype (12). Likewise, most hemophilia B patients with splicing mutations correspond have from to severe moderate to severe moderate phenotypes, consequence of the aberrant splicing that conditions the expression of the functional protein. The c.520 + 13A > G mutation in intron 5 shows moderate mild to mild moderate phenotypes (13). In addition, same substitution at the same location of the DMD gene can cause different clinical manifestations on the patient. Mutation c.3277 + 1G > A occurring in intron 25 completely removes exon 25 resulting in a mild Becker muscular dystrophy, while mutation c.6439 + 1G > A in intron 45 results in the inclusion of a shorter exon 45 leading to a severe form of Duchenne muscular dystrophy (12).

Conclusion

We described the first clinical description of a patient with OI type 1 caused by a splice variant in intron 34 of COL1A1 gene, performed a literature review of splice variants, and identified that most of them localize in the triple-helical region domain.

Data availability statement

The datasets presented in this article are not readily available because of ethical/privacy restrictions. Requests to access the datasets should be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and approved by P2019-102M. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

MD and VDC performed the literature review and wrote the paper. VIR contacted the patient, provided genetic counseling, performed the literature review, analyzed the panel results, and wrote the paper. All authors contributed to the article and approved the submitted version.

Funding

Publication of this article was funded by the Academic Articles Publication Fund of Universidad San Francisco de Quito USFQ.

Acknowledgments

We would like to thank the family of the patient for their collaboration.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fsurg.2022.986372/full#supplementary-material.

References

1. Barbirato C, Almeida MG, Milanez M, Sipolatti V, Rebouçãs MRGO, Akel AN, et al. A novel COL1A1 gene-splicing mutation (c.1875+1G > C) in a Brazilian patient with osteogenesis imperfecta. Genet Mol Res GMR. (2009) 8 (1):173–8. doi: 10.4238/vol8-1gmr563
2. Lin Y, Li X, Huang X, Zheng D, Liu Y, Lan F, et al. Hybrid minigene splicing assay verifies the pathogenicity of a novel splice site variant in the COL1A1 gene of a Chinese patient with osteogenesis imperfecta type I. Injury. (2019) 50 (12):2215–9. doi: 10.1016/j.injury.2019.10.033
3. Ju M, Bai X, Zhang T, Lin Y, Yang L, Zhou H, et al. Mutation spectrum of COL1A1/COL1A2 screening by high-resolution melting analysis of Chinese patients with osteogenesis imperfecta. J Bone Miner Metab. (2020) 38 (2):188–97. doi: 10.1007/s00774-019-01039-3
4. Li L, Cao Y, Zhao F, Mao B, Ren X, Wang Y, et al. Validation and classification of atypical splicing variants associated with osteogenesis imperfecta. *Front Genet.* (2019) 10:979. doi: 10.3389/fgene.2019.00979.

5. Marini JC, Forlino A, Cabral WA, Barnes AM, San Antonio JD, Milgrom S, et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. *Hum Mutat.* (2007) 28(3):209–21. doi: 10.1002/humu.20429

6. Scharf RJ, Scharf GJ, Stroustrup A. Developmental milestones. *Pediatr Rev.* (2016) 37(1):25–37, quiz 38–47. doi: 10.1542/pir.2014-0103

7. Lindahl K, Åström E, Rubin CJ, Grigelioniene G, Malingren B, Ljunggren Ö, et al. Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta. *Eur J Hum Genet.* (2015) 23(8):1042–50. doi: 10.1038/ejhg.2015.81

8. Sam JE, Dharmalingam M. Osteogenesis imperfecta. *Indian J Endocrinol Metab.* (2017) 21(6):903–8. doi: 10.4103/ijem.IJEM_220_17

9. Rauch F, Glorieux FH. Osteogenesis imperfecta. *Lancet.* (2004) 363(9418):1377–85. doi: 10.1016/S0140-6736(04)16051-0

10. PubChem. COL1A1—collagen type I alpha 1 chain (human) (2022). Available at: https://pubchem.ncbi.nlm.nih.gov/gene/COL1A1/human (Accessed January 20, 2022).

11. Definition of splice-site variant—NCI dictionary of genetics terms—NCI (2012). Available at: https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/splice-site-variant (Accessed January 8, 2022).

12. Anna A, Monika G. Splicing mutations in human genetic disorders: examples, detection, and confirmation. *J Appl Genet.* (2018) 59(3):253–68. doi: 10.1007/s13353-018-0444-7

13. Shen G, Gao M, Cao Q, Li W. The molecular basis of FIX deficiency in hemophilia B. *Int J Mol Sci.* (2022) 23(5):2762. doi: 10.3390/ijms23052762